Synchron brain implant Stentrode trial pause infographic

The Synchron brain implant programme has hit its first major setback: the New York company has voluntarily paused enrollment in trials of its second-generation Stentrode brain-computer interface (BCI) after the device did not perform as expected in early participants. Synchron traced the problem to the lead, the thin cable that carries brain signals from the Stentrode electrode array to the electronics implanted in the chest, and says it has found no associated safety issue. The pause, first reported by WIRED on 12 November 2026 and confirmed by trial sites, was not ordered by the US Food and Drug Administration.

Synchron is one of the best-known names in the race to give people with paralysis control of computers by thought, alongside Neuralink and others. Its pitch has always been that its device goes in through a blood vessel rather than through the skull. Here is what is known about the pause, what remains unclear, and what it means for the field.

Key takeaways on the Synchron brain implant pause

  • Enrollment is on hold in trials of the second-generation Stentrode, which has fewer electrodes and links wirelessly over Bluetooth.
  • The fault is in the lead connecting the brain-side array to the implanted electronics, not in the Stentrode itself, according to the company.
  • Synchron reports no device safety issue, and the pause was its own decision rather than an FDA action.
  • Two of five US trial sites contacted by WIRED confirmed recruitment is paused.
  • The company is bringing lead design and manufacturing in-house, building a team in San Diego and cutting jobs in New York.
  • No date has been given for restarting enrollment or for a larger pivotal trial.

How the Stentrode works

Most implanted BCIs require a neurosurgeon to open the skull and place electrodes on or in the brain. Synchron’s approach borrows from interventional cardiology and stroke care. A mesh electrode array, similar to a stent, is threaded through the jugular vein and positioned in a blood vessel on the surface of the motor cortex. A lead then runs through the vein to a small receiver and transmitter placed under the skin of the chest, which sends the decoded signals to a computer or phone.

That lead is the component now in question. It must survive constant movement of the neck and chest while carrying very small electrical signals over a long path, which makes it a demanding piece of engineering. Synchron has not disclosed how the lead failed, how often, or in how many patients.

Synchron at a glance

ItemDetail
DeviceStentrode endovascular brain-computer interface
Implant routeJugular vein to a vessel over the motor cortex; no open-skull surgery
First US studyCOMMAND early feasibility study, 6 patients with severe paralysis, 3 US centres
COMMAND safety resultNo device-related serious adverse events causing death or permanent disability at 12 months (reported 2024)
Second-generation deviceFewer electrodes, Bluetooth wireless link
Current statusTrial enrollment paused over lead performance (November 2026)
FundingUSD 200 million round closed in autumn 2025, valuation reported near USD 1 billion

Why this setback matters

The COMMAND study, the first FDA investigational device exemption trial of a permanently implanted BCI, met its primary safety goal in all six participants. The next step was meant to be a larger pivotal trial that could support an FDA marketing application, and the second-generation studies were the bridge to that. A pause at this point is likely to push back the timeline for a commercial product, although the company has not given new dates.

The context is also important. A design or component fault found and fixed during early trials is the system working as intended. Choosing to stop enrollment, redesign the lead and upgrade the full system before adding patients suggests Synchron wants a cleaner dataset going into a pivotal study rather than one weighed down by device failures. Companies building cochlear implants, deep brain stimulators and pacemakers have gone through similar lead redesigns.

What it means for current participants

Some participants have already received the second-generation device. Synchron says it will support all Stentrode recipients for life. One trial coordinator told WIRED the pause was not safety related. Because the device sits inside a blood vessel, the lead question is mainly about signal quality and the user’s ability to control a computer, not about immediate risk to the brain, based on what has been disclosed so far.

The wider BCI race and the market

Regulators are paying closer attention to BCIs as more companies reach the clinic. China has already moved to set standards for AI in the field, as we reported in China’s first AI standard for brain-computer interface medical devices. For more device news, see our Medical Device section.

Acumen Research and Consulting valued the global brain-computer interface market at USD 1.9 billion in 2022 and projects USD 8.9 billion by 2032, a 16.8% compound annual growth rate. Acumen found that non-invasive BCIs held the largest share, with North America the biggest region and Asia-Pacific growing fastest. Implanted systems like the Stentrode are a small, early part of that total, and the report dates from October 2023, so the figures are indicative.

Open questions

  • How many second-generation devices were implanted, and how many showed the lead problem?
  • Will existing participants need a procedure to replace or upgrade their leads?
  • When will the upgraded system be ready, and will it need fresh FDA review before enrollment restarts?
  • What is the unrevealed device the new San Diego team is also working on?

FAQ

Why did Synchron pause its brain implant trials?

The lead that carries signals from the Stentrode to the implanted electronics did not perform as expected in early participants of the second-generation trials. Synchron paused enrollment to redesign and upgrade the system.

Is the Synchron Stentrode safe?

Synchron says it has found no safety issue linked to the lead problem, and its first US study reported no device-related serious adverse events causing death or permanent disability over 12 months. Larger trials are still needed.

Did the FDA stop the Synchron trial?

No. The company says the pause was voluntary and not directed by the FDA.

How is Synchron different from Neuralink?

Synchron’s Stentrode is delivered through a vein and sits inside a blood vessel on the brain’s surface, avoiding open-skull surgery. Neuralink’s device is placed by opening the skull and inserting threads into brain tissue.

Sources: WIRED report (12 November 2026) as summarised by Becker’s Hospital Review and Implantable Device; Synchron COMMAND study release. Market data: Acumen Research and Consulting. Not medical or investment advice. Last updated 15 November 2026.

By Simone Lamb

Simone Lamb is the editor of Medgadget.in, covering healthcare technology, medical devices, and the latest developments in digital health.

Leave a Reply

Your email address will not be published. Required fields are marked *